Colgate-Palmolive Company's Hill's Pet Nutrition reported robust fourth-quarter results for 2025, driven primarily by growth in the cat segment, despite experiencing some weakness in the dog category. In the U.S., the business rebounded with over 5% growth, excluding private label items, and positive volume performance. However, trends like "Buy Canadian" impacted sales in Canada.
Read More
A significant contributor to growth has been the prescription diet segment, which has seen particularly strong performance, enhancing market share and affirming confidence in Hill's ability to navigate sluggish overall market conditions. While private label competition reduced volume by 360 basis points, Hill's managed to achieve an underlying volume growth of 2%, with broad-based gains, albeit with softness in the dry food category.
Therapeutic products continue to be a vital growth driver, with Prescription Diet not only delivering robust growth but also supporting profit margins. Innovation grounded in science plays a key role in market success and helps retailers create value. Although slower pet adoptions have slowed category growth, trends toward premiumization and ongoing product innovation present new opportunities.
Strategic acquisitions, such as Prime100, have exceeded expectations thanks to strong execution and a science-backed, vet-endorsed approach. The brand's focus on dermatological health and advancements in fresh nutrition aligns with its long-term growth strategy. By the end of 2025, the brand saw increased shelf share, reinforcing its competitive edge as it moves into a potentially more challenging 2026. Supply chain enhancements have facilitated greater output of innovative products, particularly from the Tonganoxie plant, which is enhancing global distribution capabilities.
Hill’s brand has continued to expand across key retail environments despite increasing competition in the latter half of the year. Overall, the emphasis on a science-driven strategy continues to yield positive results, bolstered by ongoing investments in brand advertising. According to Zacks, Colgate-Palmolive's shares have appreciated by 9.5% over the past six months, in contrast to a 6.5% decline in the industry. Currently, Colgate-Palmolive holds a Zacks Rank of #3 (Hold). From a valuation perspective, the company has a forward price-to-earnings ratio of 21.57, surpassing the industry average of 17.43. The Zacks Consensus Estimate predicts year-over-year earnings growth of 5.4% for the current fiscal year and 6.7% for the next.